These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 20932675)

  • 61. Locally advanced prostatic cancer: long-term toxicity outcome after three-dimensional conformal radiation therapy--a dose-escalation study.
    Zelefsky MJ; Fuks Z; Wolfe T; Kutcher GJ; Burman C; Ling CC; Venkatraman ES; Leibel SA
    Radiology; 1998 Oct; 209(1):169-74. PubMed ID: 9769828
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09.
    Zietman AL; Bae K; Slater JD; Shipley WU; Efstathiou JA; Coen JJ; Bush DA; Lunt M; Spiegel DY; Skowronski R; Jabola BR; Rossi CJ
    J Clin Oncol; 2010 Mar; 28(7):1106-11. PubMed ID: 20124169
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Five-year follow-up using a prostate stent as fiducial in image-guided radiotherapy of prostate cancer.
    Carl J; Sander L
    Acta Oncol; 2015 Jun; 54(6):862-7. PubMed ID: 25539443
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy).
    Ryu JK; Winter K; Michalski JM; Purdy JA; Markoe AM; Earle JD; Perez CA; Roach M; Sandler HM; Pollack A; Cox JD
    Int J Radiat Oncol Biol Phys; 2002 Nov; 54(4):1036-46. PubMed ID: 12419429
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Incidence of and factors related to late complications in conformal and conventional radiation treatment of cancer of the prostate.
    Schultheiss TE; Hanks GE; Hunt MA; Lee WR
    Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):643-9. PubMed ID: 7790250
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Reduction in acute morbidity using hypofractionated intensity-modulated radiation therapy assisted with a fluoroscopic real-time tumor-tracking system for prostate cancer: preliminary results of a phase I/II study.
    Kitamura K; Shirato H; Shinohara N; Harabayashi T; Onimaru R; Fujita K; Shimizu S; Nonomura K; Koyanagi T; Miyasaka K
    Cancer J; 2003; 9(4):268-76. PubMed ID: 12967137
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Toxicity following high-dose three-dimensional conformal and intensity-modulated radiation therapy for clinically localized prostate cancer.
    Shu HK; Lee TT; Vigneauly E; Xia P; Pickett B; Phillips TL; Roach M
    Urology; 2001 Jan; 57(1):102-7. PubMed ID: 11164152
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial.
    Dearnaley DP; Khoo VS; Norman AR; Meyer L; Nahum A; Tait D; Yarnold J; Horwich A
    Lancet; 1999 Jan; 353(9149):267-72. PubMed ID: 9929018
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Target localization and toxicity in dose-escalated prostate radiotherapy with image-guided approach using daily planar kilovoltage imaging.
    Nath SK; Sandhu AP; Sethi RA; Jensen LG; Rosario MD; Kane CJ; Parsons JK; Millard FE; Jiang SB; Rice RK; Pawlicki T; Mundt AJ
    Technol Cancer Res Treat; 2011 Feb; 10(1):31-7. PubMed ID: 21214286
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Moderate dose escalation in three-dimensional conformal localized prostate cancer radiotherapy: single-institutional experience in 398 patients comparing 66 Gy versus 70 Gy versus 74 Gy.
    Goldner G; Dimopoulos J; Kirisits C; Pötter R
    Strahlenther Onkol; 2009 Jul; 185(7):438-45. PubMed ID: 19714305
    [TBL] [Abstract][Full Text] [Related]  

  • 71. High dose versus conventional dose in external beam radiotherapy of prostate cancer: a meta-analysis of long-term follow-up.
    Hou Z; Li G; Bai S
    J Cancer Res Clin Oncol; 2015 Jun; 141(6):1063-71. PubMed ID: 25173623
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Prospective Phase II Trial of Once-weekly Hypofractionated Radiation Therapy for Low-risk Adenocarcinoma of the Prostate: Late Toxicities and Outcomes.
    Zimmermann M; Taussky D; Menkarios C; Vigneault É; Beauchemin MC; Bahary JP; Martin AA; Diaz de Bedoya LV; Lambert C
    Clin Oncol (R Coll Radiol); 2016 Jun; 28(6):386-92. PubMed ID: 26782838
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Factors influencing incidence of acute grade 2 morbidity in conformal and standard radiation treatment of prostate cancer.
    Hanks GE; Schultheiss TE; Hunt MA; Epstein B
    Int J Radiat Oncol Biol Phys; 1995 Jan; 31(1):25-9. PubMed ID: 7995764
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Association of a XRCC3 polymorphism and rectum mean dose with the risk of acute radio-induced gastrointestinal toxicity in prostate cancer patients.
    Fachal L; Gómez-Caamaño A; Peleteiro P; Carballo A; Calvo-Crespo P; Sánchez-García M; Lobato-Busto R; Carracedo A; Vega A
    Radiother Oncol; 2012 Dec; 105(3):321-8. PubMed ID: 23075580
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Conditional Risk and Predictive Factors Associated With Late Toxicity in Patients With Prostate Cancer Treated With External Beam Radiation Therapy Alone in the Randomized Trial RTOG 0126.
    Alexander GS; Krc RF; Assif JW; Sun K; Molitoris JK; Tran P; Rana Z; Mishra MV
    Int J Radiat Oncol Biol Phys; 2024 Nov; 120(4):990-998. PubMed ID: 38825251
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Short-course accelerated radiotherapy in palliative treatment of advanced pelvic malignancies: a phase I study.
    Caravatta L; Padula GD; Macchia G; Ferrandina G; Bonomo P; Deodato F; Massaccesi M; Mignogna S; Tambaro R; Rossi M; Flocco M; Scapati A; Scambia G; Pacelli F; Valentini V; Cellini N; Morganti AG
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e627-31. PubMed ID: 22580117
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy: dose-volume analysis of a phase II dose-escalation study.
    Harsolia A; Vargas C; Yan D; Brabbins D; Lockman D; Liang J; Gustafson G; Vicini F; Martinez A; Kestin LL
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1100-9. PubMed ID: 17967304
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Minimal toxicity after proton beam therapy for prostate and pelvic nodal irradiation: results from the proton collaborative group REG001-09 trial.
    Chuong MD; Hartsell W; Larson G; Tsai H; Laramore GE; Rossi CJ; Wilkinson JB; Kaiser A; Vargas C
    Acta Oncol; 2018 Mar; 57(3):368-374. PubMed ID: 29034790
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Toxicity of the lower gastrointestinal tract and its predictive factors after 72Gy conventionally fractionated 3D conformal radiotherapy of localized prostate cancer.
    Stankovic V; Nikitovic M; Pekmezovic T; Pekmezovic D; Kisic Tepavcevic D; Stefanovic Djuric A; Saric M
    J BUON; 2016; 21(5):1224-1232. PubMed ID: 27837627
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Absorbable hydrogel spacer use in men undergoing prostate cancer radiotherapy: 12 month toxicity and proctoscopy results of a prospective multicenter phase II trial.
    Uhl M; Herfarth K; Eble MJ; Pinkawa M; van Triest B; Kalisvaart R; Weber DC; Miralbell R; Song DY; DeWeese TL
    Radiat Oncol; 2014 Apr; 9():96. PubMed ID: 24758224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.